Royalty Pharma plc
RPRXHealthcare|Medical - Pharmaceuticals|US
$67.30
-0.27 (-0.40%)
DCF Value
$20.18
Tangible Book / Share
$19.93
Graham Number
$22.85
Cash / Share
$1.22
About
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Stock Price
+65.0%(1Y)
1M
+19.7%
3M
+18.5%
6M
+32.5%
YTD
+74.2%
1Y
+74.6%
3Y
+143.7%
5Y
+68.9%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$29.97B
Employees100 (+1% YoY)
CEOPablo Legorreta
IPO DateJun 16, 2020
Beta0.41
52-Week Range$37.31 – $69.77
Avg Volume3,046,812
ExchangeNASDAQ
Websiteroyaltypharma.com
Ownership
Float94.0%
Shares Outstanding445.3M
Recent Insider Trades
Coyne Terrance P.CONVERSION
Nov 6, 202610,000 shares
Coyne Terrance P.CONVERSION
Nov 6, 2026150,000 shares
Coyne Terrance P.CONVERSION
Nov 6, 202615,000 shares
Coyne Terrance P.CONVERSION
Nov 6, 2026100,000 shares
Coyne Terrance P.AWARD
Nov 4, 20267,122 shares
Peers
GROYGold Royalty Corp.
$722.8MOROR Royalties Inc.
$6.79BRGLDRoyal Gold, Inc.
$22.56BRecent News
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug
Nov 8, 2026 · fool.com
Royalty Pharma (RPRX) Upgraded to Buy: What Does It Mean for the Stock?
Nov 6, 2026 · zacks.com
Royalty Pharma: Unique, Diversified Life Science And Biopharma Pure Play
Nov 4, 2026 · seekingalpha.com
Royalty Pharma Q3 Earnings Call Highlights
Nov 4, 2026 · marketbeat.com
Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript
Nov 4, 2026 · seekingalpha.com
Data last updated: Nov 9, 2026, 04:32 AM